On June 15, 2010
HGSI’s Hepatitis Drug Zalbin: When an FDA Rejection Is Good News
The FDA is none too pleased with Human Genome Sciences’ (HGSI) new hepatitis C drug Zalbin (albinterferon alfa-2b), but that may be a blessing in disguise.
No tags for this post.
0 Comments